Literature DB >> 11298604

Induction of Toll-like receptor 4 in granulocytic and monocytic cells differentiated from HL-60 cells.

Y Mita1, K Dobashi, T Nakazawa, M Mori.   

Abstract

Toll-like receptor 4 (TLR4) is the main protein expressed on the cell surface and is an essential receptor for lipopolysaccharide (LPS) signalling in human peripheral blood leucocytes. We examined TLR4 expression and the functional response to LPS in retinoic acid-treated HL-60 cells (HL-60-derived granulocytic cells) and interferon-gamma-treated HL-60 cells (HL-60-derived monocytic cells). Slight TLR4 expression was induced in HL-60-derived granulocytic cells, while strong induction was seen in HL-60-derived monocytic cells. LPS induced interleukin 1beta (IL-1beta) production and TLR4 expression in HL-60-derived monocytic cells, but not HL-60-derived granulocytic cells. These data indicate different responses to LPS in the cells. TLR4 surface expression paralleled LPS-induced phagocytosis and TLR4-neutralizing antibody partially inhibited LPS-induced IL-8 production in HL-60-derived monocytic cells, but not in HL-60-derived granulocytic cells. These results suggest that HL-60-derived monocytic cells are partially activated via TLR4, but that HL-60-derived granulocytic cells are not activated via TLR4.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298604     DOI: 10.1046/j.1365-2141.2001.02658.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Fibronectin promotes the phorbol 12-myristate 13-acetate-induced macrophage differentiation in myeloid leukemia cells.

Authors:  Gunes Esendagli; Hande Canpinar; Guldal Yilmaz; F Figen Kaymaz; Emin Kansu; Dicle Guc
Journal:  Int J Hematol       Date:  2009-01-23       Impact factor: 2.490

2.  Presentation matters: Impact of association of amphiphilic LPS with serum carrier proteins on innate immune signaling.

Authors:  Loreen R Stromberg; Heather M Mendez; Jessica Z Kubicek-Sutherland; Steven W Graves; Nicolas W Hengartner; Harshini Mukundan
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.